Clinical trials: Neoplasm Recurrence, Local
Lymphoma
Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma
The purpose of this study is to compare the safety and effects of atezolizumab with low dose radiation on people with relapsed or refractory follicular lymphoma, In this study, the patient will get either atezolizumab with low…
- Trial name
- NCT03465891
- Testing
- atezolizumab, Low- Dose, Local Radiotherapy
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
RATIONALE: Atorvastatin calcium and celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atorvastatin calcium together with celecoxib may kill more tumor cells.
- Trial name
- NCT01220973
- Testing
- atorvastatin calcium, celecoxib, laboratory biomarker analysis
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Rutgers, The State University of New Jersey
Breast Neoplasms
Regional Anesthesia and Breast Cancer Recurrence
In this multi-center trial, Stage 1-3 patients having mastectomies or isolated lumpectomy with axillary node dissection will be randomly assigned to thoracic epidural or paravertebral anesthesia/analgesia, or to general…
- Trial name
- NCT00418457
- Testing
- General anesthesia and opioids, Regional analgesia and propofol
- Where
- 6 sites in United States, Austria and 4 more
- Volunteers
- 2,108 people
- Sponsor
- The Cleveland Clinic
Recurrent Head and Neck Squamous Cell Carcinoma, Second Primary Squamous Cell Carcinoma of the Head and Neck
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer
This phase I/II trial studies the side effects and how well bintrafusp alfa and stereotactic body radiation therapy work in treating patients with head and neck squamous cell cancer that has come back (recurrent) or has occurred…
- Trial name
- NCT04220775
- Testing
- Bintrafusp Alfa, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Fulvestrant in Treating Patients With Recurrent Prostate Cancer
RATIONALE: Estrogen may cause the growth of prostate cancer cells. Hormone therapy using fulvestrant may fight prostate cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00217464
- Testing
- fulvestrant
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Roswell Park Cancer Institute
Cervical Cancer, Endometrial Cancer
CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Cervical Cancer, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00610740
- Testing
- topical gemcitabine hydrochloride, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Prostate Cancer, Recurrent Prostate Cancer
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
MMR-deficient cancers of any histologic type appear to be very sensitive to PD-1 blockade with pembrolizumab, and similar data are also beginning to emerge for nivolumab and other immune checkpoint inhibitors.
- Trial name
- NCT04019964
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colon Polyp, Colon Adenoma
Hybrid APC Assisted EMR for Large Colon Polyps
The purpose of this study to evaluate and examine whether use of Hybrid Argon Plasma Coagulation (APC) as an adjunct to endoscopic mucosal resection (EMR) will reduce the risk of residual or recurrent neoplasia at 6 months.
- Conditions
- Colon Polyp, Colon Adenoma, Colon Cancer
- Trial name
- NCT03390907
- Testing
- Hybrid APC
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Milton S. Hershey Medical Center